Amgen Stock Surges on Positive Trial Results

Amgen's stock has been on the rise after announcing positive results from its Phase 3 OASIZ 301 trial for dazodalibep in systemic Sjögren’s disease. The company reported that its late-stage asset met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in disease activity at Week 48.

The stock has gained 3.5% to $407.42, with technical indicators showing bullish momentum and a likely consolidation in the $398.56 to $416.28 range over the next 2-3 days.

Amgen plans to present detailed study data at an upcoming medical meeting, which is expected to further maintain market focus on its therapeutic innovation.